Antila Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.67 M
as on 24-10-2024
- Company Age 14 Year, 19 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.25 Cr
as on 24-10-2024
- Revenue 99.80%
(FY 2023)
- Profit 146.55%
(FY 2023)
- Ebitda 86.27%
(FY 2023)
- Net Worth 81.37%
(FY 2023)
- Total Assets 41.91%
(FY 2023)
About Antila Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.67 M.
The company currently has active open charges totaling ₹5.25 Cr.
Sanjay Shah, Rutwa Shah, and Parth Shah serve as directors at the Company.
- CIN/LLPIN
U24230GJ2010PTC063306
- Company No.
063306
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Antila Lifesciences Private Limited offer?
Antila Lifesciences Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Cardiovascular Drugs & Medication, Kidney Drugs, Ayurvedic,Herbal Products & Medicine, Herbal Capsules, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Antila Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rutwa Shah  | Director | 21-Dec-2010 | Current |
| Sanjay Shah | Director | 21-Dec-2010 | Current |
| Parth Shah | Director | 21-Dec-2010 | Current |
Financial Performance of Antila Lifesciences.
Antila Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 99.8% increase. The company also saw a substantial improvement in profitability, with a 146.55% increase in profit. The company's net worth Soared by an impressive increase of 81.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Antila Lifesciences?
In 2023, Antila Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Jul 2024 | ₹3.50 M | Open |
Others Creation Date: 04 Nov 2023 | ₹4.90 Cr | Open |
How Many Employees Work at Antila Lifesciences?
Unlock and access historical data on people associated with Antila Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Antila Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Antila Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
